Clearance of the Janus Kinase 2 (JAK2) V617F mutation after allogeneic stem cell transplantation in a patient with myelofibrosis with myeloid metaplasia

American Journal of Hematology

Volumn 82, Issue 5, 2007, Pages 400-402

  Ruiz Argüelles, Guillermo J ^a,b   Garcés Eisele, Javier ^b,c   Reyes Núñez, Virginia ^b   Ruiz Delgado, Guillermo J ^d   Rosillo, Carlos ^e   Camoriano, John K ^f  

^a CENTRO DE HEMATOLOGÍA Y MEDICINA INTERNA DE PUEBLA   (Mexico)

^b Laboratorios Clinicos de Puebla   (Mexico)

^c UNIVERSIDAD DE LAS AMÉRICAS PUEBLA   (Mexico)

^d HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

^e UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ   (Mexico)

^f MAYO CLINIC   (United States)

Author keywords

Bone marrow transplantation; JAK2 V617F mutation; Molecular remission; Myelofibrosis with myeloid metaplasia

Indexed keywords

JANUS KINASE 2;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CASE REPORT; CHIMERA; GENE; GENE EXPRESSION; GENE MUTATION; HUMAN; JAK2 GENE; MALE; MYELOFIBROSIS; MYELOID METAPLASIA; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; REMISSION; TREATMENT INDICATION; TREATMENT RESPONSE;

BIOLOGICAL MARKERS; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION, MISSENSE; MYELOFIBROSIS; MYELOID METAPLASIA; NEOPLASM PROTEINS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; POINT MUTATION; REMISSION INDUCTION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 34247487437     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20832     Document Type: Article

References (12)

1. Thompson JE. JAK protein kinase inhibitors. Drug News Perspect 2005;18:305-310.
2. Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst 1960;25:85-109.
3. Tefferi A, Gilliland G. The JAK2 V617F tyrosine kinase mutation in myeloproliferative disorders: Status report and immediate implication for disease classification and diagnosis. Mayo Clin Proc 2005;80:947-958.
4. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythemia vera. Nature 2005;434:1144-1148.
5. Ruiz-Argüelles GJ, Garcés-Eisele J, Reyes-Núñez V, et al. Assessment of residual disease in acute leukemia by means of polymerase chain reaction: A prospective study in a single institution. Rev Invest Clín Méx 2000,52:118-124.
6. Ruiz-Argüelles GJ, López-Martínez B, Ramírez-Cabrera JM, Reyes-Nuñez V, Rodríguez-Cedeño H, Garcés-Eisele J. Molecular monitoring of the treatment of patients with BCR/ABL (+) chronic myelogenous leukemia. Rev Invest Clin Méx 2001;53: 235-239.
7. Ruiz-Argüelles GJ, Morales-Toquero A, Gómez-Rangel JD, López-Martínez B, Ruiz-Delgado GJ, Reyes-Núñez V. Treatment of acute promyelocytic leukemia: A single institution experience. Rev Invest Clín Méx 2005,57:415-419.
8. Bloor AJC, Ahmed O, Dimpoulou M, et al. Reduced intensity allogeneic stem cell transplantation in patients with myelofibrosis. Brit J Haematol 2006;133 (Suppl 1):13.
9. Baxter EJ, Scott LM, Campbell PJ, et al. Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-1061.
10. Ruiz-Argüelles GJ, Gómez-Almaguer D, Gómez Rangel JD, et al. Allogeneic hematopoietic stem cell transplantation with non-myeloablative conditioning in patients with acute leukemia eligible for conventional allografting: A prospective study. Leuk Lymph 2004;45:1191-1195.
11. Tefferi A, Barosi G, Mesa RA, et al., on behalf of the IWG for myelofibrosis research and treatment (IWG-MRT). International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia. Blood 2006; 1497-1503.
12. Ruiz-Argüelles GJ, Garcés-Eisel J, Reyes-Núñez V, Ruiz-Delgado GJ, Navarro-Vázquez M, González-Carrillo M. The Janus kinase 2 (JAK2) V617F mutation in hematological malignancies in México. Rev Invest Clin Méx, in press.